Chester County News and Community Website
WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) reported third-quarter 2025 results showing a 20% year-over-year increase in total revenue to $1.37 billion, driven by strong demand across its hematology, oncology, …
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand Read More WILMINGTON, DE & CINCINNATI, OH — Incyte (NASDAQ: INCY) and Enable Injections have formed a strategic partnership to co-develop and commercialize targeted cancer therapies using Enable’s enFuse® On-Body Delivery System, …
Incyte and Enable Injections Join Forces to Advance At-Home Cancer Treatments Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that it will participate in two high-profile investor conferences in November, where company leaders will discuss ongoing innovation and pipeline progress across its …
Incyte to Highlight Innovation at Major Global Healthcare Conferences in November Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that it will release its third quarter 2025 financial results before markets open on Tuesday, October 28, 2025. The company will host a …
Incyte to Report Third Quarter 2025 Financial Results on October 28 Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has granted equity inducement awards to David H. Gardner, its newly appointed Executive Vice President and Chief Strategy Officer, under the company’s 2024 Inducement …
Incyte Grants Equity Awards to New Chief Strategy Officer David Gardner Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has appointed Dave Gardner as Executive Vice President and Chief Strategy Officer. Gardner will join the company’s Executive Leadership Team, overseeing corporate strategy and …
Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate …
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) released new 24-week interim data from its pivotal Phase 3 STOP-HS trials, showing that its oral JAK1 inhibitor povorcitinib (INCB54707) delivered sustained efficacy and …
Incyte Reports Positive 24-Week Data for Povorcitinib in Hidradenitis Suppurativa Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will highlight new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress in Paris, running September 17–20. …
Incyte to Present New Data on Dermatology Portfolio at EADV 2025 Congress Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced the launch of HS TRUTHS, an educational campaign aimed at increasing understanding of hidradenitis suppurativa (HS), a chronic inflammatory skin condition that can …
Incyte Launches HS TRUTHS Campaign to Raise Awareness of Hidradenitis Suppurativa Read More